10 results about "Gluconeogenesis" patented technology

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

The invention discloses application of thiamine in preparation of a product for treating subclinical ketosis of dairy cows, and belongs to the field of biological medicines. Tests prove that compared with dairy cows suffering from subclinical ketosis (SCK), by adding thiamine, the content of beta-hydroxybutyric acid (BHBA), the number of bacteria in milk and the number of somatic cells can be remarkably reduced, and the milk yield, the milk fat content, the acetic acid content and the A / P ratio are remarkably increased; the microbial diversity of rumen and excrement of the dairy cow can be adjusted; a metabonomics result shows that metabolite up-regulated after the thiamine is added mainly focuses on pyruvic acid metabolism, glycolysis or gluconeogenesis, tyrosine metabolism, glycerophospholipid metabolism and biosynthetic pathways of phenylalanine, tyrosine and tryptophan. The conclusion is that when thiamine is added into the SCK dairy cow, synthesis and catabolism of BHBA of an organism can be effectively regulated and controlled by adjusting the content of succinyl-coenzyme A, then subclinical ketosis is relieved, rumen fermentation is promoted, and therefore the milk yield and the milk quality are improved.

The application discloses a chrysanthemum stem and leaf active extract with improved fish heavy metal poisoning and a preparation method thereof. The chrysanthemum stem and leaf active extract is compounded by a chrysanthemum stem and leaf crude polysaccharide part and a chrysanthemum stem and leaf phenolic ketone part. The pharmacodynamic experiment results show that the chrysanthemum stem and leaf active extract has a good improvement effect on fish heavy metal poisoning. The chrysanthemum stem and leaf active extract can not only improve pathological changes such as heart and liver granuloma, kidney tubular cast, intestinal cavity expansion and gill lamella shedding caused by heavy metal poisoning, but also improve metabolic dysfunction such as taurine and hypotaurine metabolic disorder, pyruvic acid metabolic abnormality, tricarboxylic acid cycle disorder, glycolysis and gluconeogenesis disorder caused by heavy metal poisoning. The preparation method has reasonable whole preparation process design, can realize waste utilization, extends a chrysanthemum industry chain, expands a chrysanthemum resource utilization approach, is helpful to quality improvement and efficiency increase and green development of the chrysanthemum industry, and provides support for prevention and treatment of heavy metal poisoning.

The present application provides a soluble dietary fiber composition, its preparation method and application. After the soluble dietary fiber composition enters the colon, the ester bond in the alanine modified pectin is rapidly degraded, part of the chlorogenic acid is released, the secretion of anorectic hormone is stimulated, the appetite is reduced, and the heat intake is reduced; the remaining amide bond network is slowly degraded, realizing the slow and continuous release of chlorogenic acid. Lutein removes free radicals generated by fat decomposition, reducing the oxidative damage of L cells. Galactomannan and alanine modified pectin-glucan modified protein-chlorogenic acid ternary complex synergize to improve the molar ratio of butyric acid / propionic acid: propionic acid enhances satiety through intestinal gluconeogenesis, and butyric acid stimulates the secretion of GLP-1 / PYY, realizing endogenous appetite suppression. Galactomannan absorbs water to form a lubricating gel, softening the stool and increasing the stool volume; the ternary complex degrades to produce short-chain fatty acids, optimizing the intestinal microenvironment and enhancing gastrointestinal peristalsis, both of which synergistically improve constipation.

This invention relates to the field of feed additive technology, specifically to a compound plant-seaweed feed additive for reducing methane emissions in ruminants and its preparation method. It comprises the following raw materials in parts by weight: 40-60 parts sorghum husk powder, 30-50 parts purple sweet potato powder, 0.5-5 parts functional additives, 5-10 parts red algae, 5-10 parts brown algae, 5-12 parts *Lactobacillus plantarum*, 3-8 parts chitosan, 2-6 parts essential oil, 2-5 parts 3-nitrooxypropanol, 10-15 parts *Scutellaria baicalensis*, 8-12 parts *Codonopsis pilosula*, 3-8 parts *Isatis indigotica*, and 5-18 parts modified zeolite. Through the regulation of *Lactobacillus plantarum* and chitosan, the energy originally used to generate methane is converted into propionic acid. Propionic acid is a major gluconeogenic precursor in ruminants, which is directly converted into glucose for milk production or muscle growth.

The invention discloses an application of an endogenous metabolite micromolecule GGOH in preparation of liver cancer drugs, the structural formula of GGOH is as shown in formula (I): GGOH can be spontaneously converted into GGPP after entering the liver, and the GGOH can specifically up-regulate gluconeogenesis in the liver and reduce glycolysis level, so that the glucose metabolism steady state of the liver is improved, and the occurrence and development of fatty liver diseases are inhibited. The invention discloses the application of the endogenous metabolite micromolecule GGOH in preparing the fatty liver disease medicine or treating the liver cancer for the first time, clarifies the key regulation effect of the GGOH / GGPP level in the occurrence and development of the fatty liver disease, opens up a new direction for treating the fatty liver disease related to metabolic disorder, and has important scientific significance and clinical application prospects.

The invention relates to carbon quantum dots based on taurine and glucose and application of the carbon quantum dots in preparation of synergistic hypoglycemic drugs. The carbon quantum dot is prepared from glucose and taurine according to the molar ratio of 1: 10-10: 10 through a hydrothermal method, the particle size is 2-10 nm, and the carbon quantum dot has a graphitized lattice structure. The carbon quantum dot has high-efficiency scavenging capacity on hydroxyl free radicals and nitrogen free radicals. A zebra fish model experiment proves that the carbon quantum dot inhibits a gluconeogenesis process by inhibiting glucagon gene expression, remarkably reduces pancreatic cell apoptosis induced by high glucose, reduces an oxidative stress level, and realizes efficient blood glucose reduction through cooperation of multiple mechanisms. Compared with a taurine monomer, the carbon quantum dot has the advantages that the cardiac toxicity is obviously reduced under the same concentration, and the safety problem of high-dose use of taurine is solved. The preparation method disclosed by the invention is simple and low in cost, and the obtained carbon quantum dots have the characteristics of efficient blood glucose reduction and high safety, and can be used for preparing medicines for treating type 2 diabetes mellitus.

This invention relates to the field of animal feed technology and discloses a compound nutritional feed suitable for the growth and development of Ili horses in high-altitude and cold regions. The feed comprises 88-92 parts roughage and 8-12 parts solid-dispersed microspheres. The solid-dispersed microspheres are made of hydrogenated palm oil, calcium propionate, anhydrous citric acid, and lysophosphatidylcholine, and have a lipid crystalline network structure. In an aqueous environment, the lysophosphatidylcholine within the microspheres establishes hydration channels, promoting water penetration and triggering an in-situ acid-base metathesis reaction between calcium propionate and anhydrous citric acid. The resulting liquid free propionic acid causes a sharp drop in the local melting point of the microspheres, leading to the disintegration of the macroscopic structure. This invention can simultaneously release free propionic acid and hydrogenated palm oil, providing energy through gluconeogenesis and intestinal enzymatic hydrolysis, respectively, achieving a dual-effect synergistic energy supply from carbohydrates and lipids. This meets the energy metabolism needs of Ili horses in high-altitude and cold environments and exhibits good long-term storage stability.

The invention discloses health-care tea for reducing blood sugar. The health-care tea is prepared from the following raw materials in parts by weight: 35-82 parts of gynostemma pentaphylla, 280-340 parts of dark green tea, 35-82 parts of astragalus membranaceus, 20-50 parts of herba epimedii, 5-14 parts of radix rehmanniae, 20-50 parts of corn stigma, 2-8 parts of liquorice and 7-22 parts of hawthorn. The traditional Chinese medicine composition is reasonable in compatibility, wide in raw material source and simple in preparation method, has an obvious effect of inhibiting gluconeogenesis, can also improve the content of liver glycogen, has the efficacy of reducing blood sugar, realizes regulation and recovery of human body balance, and achieves a stable and healthy state. The adopted traditional Chinese medicines are all natural medicinal materials, are safe and effective, and have no toxic or side effect.

The invention discloses double-stranded siRNA (small interfering Ribonucleic Acid) targeting liver Sam68 and application of the double-stranded siRNA in metabolic syndrome related diseases, and relates to the field of biological medicines. The double-stranded siRNA comprises a positive-sense strand and an antisense strand complementary to the positive-sense strand, the positive-sense strand is a modified or unmodified sequence of which the nucleotide sequence is shown as SEQ ID NO.41; the antisense strand is a modified or unmodified sequence of which the nucleotide sequence is as shown in SEQ ID NO. 42. The double-chain siRNA designed and synthesized on the basis of Sam68 can realize potent, dose-dependent and liver-limited Sam68 knock-down in vivo, inhibits liver gluconeogenesis by down-regulating glucagon signals, can reduce fasting blood-glucose, improve insulin sensitivity and protect diabetic liver from being damaged, and can be used for treating diabetic liver diseases such as diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus and diabetes mellitus. A novel long-acting nucleic acid medicine is provided for diabetes, obesity, hypercholesterolemia, atherosclerosis and other metabolic syndrome related diseases.